SI-BONE, Inc.

112 articles with SI-BONE, Inc.

• SI-BONE Announces Pricing of Public Offering of Common Stock - Oct 15, 2020

  10/15/2020

  SI-BONE, Inc. announced the pricing of its underwritten public offering of 3,190,053 shares of its common stock at a price to the public of $22.00 per share.

• SI-BONE Announces Launch of Public Offering of Common Stock - Oct 14, 2020

  10/14/2020

  SI-BONE, Inc., a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, announced that it has commenced an underwritten public offering of 3,190,053 shares of its common stock.

• SI-BONE Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and Provides Full Year 2020 Revenue Guidance

  10/8/2020

  SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced preliminary unaudited revenue for the three and nine months ended September 30, 2020.

• SI-BONE to Present at the 2020 Cantor Global Healthcare Conference

  9/2/2020

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that the company will be participating in the upcoming 2020 Cantor Global Healthcare Conference.

• SI-BONE to Present at the Morgan Stanley 18th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference

  9/1/2020

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming Morgan Stanley 18 th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference. For the Morgan Stanley Global Healthcare Conference, SI-BONE’s management is scheduled for a Fireside Chat on Tuesday, Septemb

• SI-BONE, Inc. Reports Second Quarter 2020 Financial Results

  8/3/2020

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended June 30, 2020.

• SI-BONE to Present at the 40th Annual Canaccord Genuity Growth Conference

  7/30/2020

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 40th Annual Canaccord Genuity Growth Conference that is being held virtually.

• SI-BONE To Report Second Quarter 2020 Financial Results on August 3, 2020

  7/21/2020

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced it will report financial results for the second quarter of 2020 after market close on Monday, August 3, 2020.

• SI-BONE, Inc. Announces $40 Million Debt Re-Financing

  6/1/2020

  SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that it has re-financed its existing credit facility. Proceeds from the new $40 million, five-year term loan will be used to repay SI-BONE’s prior $40 million term loan obligation in its entirety.   SI-BONE’s new term loan bears interest at a rate per annum equal to 9.40%

• SI-BONE, Inc. Announces Aetna Establishes Positive Coverage for MIS SI Joint Fusion using the Triangular iFuse Implant System

  5/29/2020

  SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that Aetna has established a positive coverage policy for minimally invasive SI joint fusion.

• Notice of Change of Location of Annual Meeting of Stockholders of SI-BONE, Inc. to Be Held on June 16, 2020SI-BONE, Inc. Announces Change to Virtual-only Format for 2020 Annual Meeting of Stockholders

  5/27/2020

  SI-BONE, Inc. announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, SI-BONE is changing its 2020 Annual Meeting of Stockholders to a virtual-only format that will be held via live audio webcast.

• SI-BONE to Present at the Bank of America Securities 2020 Health Care Conference

  5/5/2020

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that the company will be participating in the upcoming Bank of America Securities 2020 Health Care Conference that is being held virtually.

• SI-BONE, Inc. Reports First Quarter 2020 Financial Results

  5/4/2020

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended March 31, 2020.

• SI-BONE To Report First Quarter 2020 Financial Results on May 4, 2020

  4/22/2020

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced it will report financial results for the first quarter of 2020 after market close on Monday, May 4, 2020.

• SI-BONE, Inc. Provides Business Update in Response to COVID-19 Pandemic

  4/2/2020

  SI-BONE, Inc. provided an update on the actions it is taking to support patients, customers, and employees while maintaining business continuity in response to the coronavirus pandemic.

• SI-BONE, Inc. Reports Fourth Quarter and Full Year 2019 Financial ResultsReiterates Full Year 2020 Financial Outlook

  3/9/2020

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter and full year ended December 31, 2019.

• SI-BONE To Report Fourth Quarter 2019 Financial Results on March 9, 2020

  2/19/2020

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced it will report financial results for the fourth quarter of 2019 after market close on Monday, March 9, 2020.

• SI-BONE Announces Pricing of Public Offering of Common Stock

  1/23/2020

  SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced the pricing of its public offering of 4,300,000 shares of its common stock at a price to the public of $21.50 per share.

• SI-BONE Announces Launch of Public Offering of Common Stock

  1/21/2020

  SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that it has commenced an underwritten public offering of 4,300,000 shares of its common stock.

• SI-BONE Reports Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2019 and Provides Full Year 2020 Revenue Guidance

  1/9/2020

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced preliminary unaudited revenue for the fourth quarter and full year 2019.